SCHEMBL2200569

SCHEMBL2200569

COc1ccc(-c2cc(C(C)(C)C)nc3[nH]nc(N)c23)cc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.46
ABL1 P00519 5/20 0.46
EGFR P00533 5/20 0.46
HCK P08631 5/20 0.46
SRC P12931 5/20 0.46
PIK3CA P42336 5/20 0.46
PIK3CB P42338 5/20 0.46
MTOR P42345 5/20 0.46
PIK3CG P48736 5/20 0.46
EPHB4 P54760 5/20 0.46
PRKDC P78527 5/20 0.46
PI4KB Q9UBF8 5/20 0.46
KDR P35968 5/20 0.46
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 2/20 0.38
ACHE P22303 3/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GRK6 P43250 1/20 0.38
APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2200723 0.86 KDM4E (0.41) PIK3CDABL1EGFRHCKSRC
SCHEMBL2203362 0.81 KDM4E (0.50) PIK3CDABL1EGFRHCKSRC
SCHEMBL2230711 0.80 BTK (0.49) ABL1EGFRSRCPIK3CGKDR
SCHEMBL2204901 0.80 ALDH1A1 (0.39) ABL1EGFRKDRKDM4EHSD17B10
SCHEMBL2821058 0.80 KDR (0.44) ABL1SRCKDRACHEMAPT
SCHEMBL2228840 0.80 KDR (0.42) PIK3CDABL1EGFRSRCPIK3CA
SCHEMBL2198786 0.79 PIK3CD (0.40) PIK3CDABL1EGFRSRCPIK3CA
SCHEMBL2202380 0.79 ALDH1A1 (0.46) EGFRKDRKDM4EHSD17B10ACHE
SCHEMBL2203347 0.78 JAK2 (0.31) KDRKITFLT3
SCHEMBL2816031 0.77 KDR (0.56) ABL1EGFRSRCEPHB4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846402-B1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER IP GMBH (DE) 2014-02-26 EP disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-7977325-B2 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2011-07-12 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents GENESYS CLOUD SERVICES, INC. 2009-01-29 US disclosed
EP-1846402-A1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES Bayer Schering Pharma Aktiengesellschaft (DE) 2007-10-24 EP disclosed
WO-2006063805-A1 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES BAYER SCHERING PHARMA AKTINGESELLSCHAFT (DE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030010-A1 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents MAP4K2, ABL1, MAP4K3 PIK3CD 532/4885ABL1 2/4885EGFR 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.